Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

245 First Street, 18th Floor, Cambridge, United States

Invest2live Apr. 4 at 2:24 PM

$NOK 105% already; congrats 🌿🎈🌿 Checkout $RXRX and $BDTX

0 · Reply

jarias115 Apr. 4 at 11:54 AM

$BDTX I love how this just jumps on no news.

1 · Reply

Knot2 Apr. 2 at 6:23 PM

$BDTX I’m in

0 · Reply

Stock_Squatch_Watcher Apr. 2 at 2:35 PM

$BDTX 😎✌️🫈

0 · Reply

captainblacktop Apr. 2 at 2:29 PM

$BDTX only thing I have that's green..

0 · Reply

Jafo333isme Apr. 1 at 7:59 PM

$BDTX today looks a lot like it traded on 2/24. Hmm...

0 · Reply

pzthk6 Apr. 1 at 2:03 PM

$BDTX Ive been in play for a long time, nice to see positive momentum. On good PR , this is a 200%+ jumper.

0 · Reply

frankwa Apr. 1 at 2:01 PM

$BDTX any news today to create the big pop in price?

0 · Reply

Stock_Squatch_Watcher Apr. 1 at 1:13 AM

$BDTX I get we are waiting on news, but dang this board is quiet 🤐 GLTA✌🍀🫈

0 · Reply

Stock_Squatch_Watcher Mar. 27 at 1:30 PM

$BDTX Would be interesting to know if Servier is in the 1535 lung partnering mix. A year ago they licensed 4933, so they are playing in this space. It would make sense as they have already vetted BDTX as a company. If this actually occurred, and the brain 🧠 study showed good IA/FA data, which will not take nearly as long as the lung 🫁 study, it would not take much (IMO) for Servier to just say, yes, we’ll take that too, and just acquire BDTX outright. BDTX is roughly 20-25 people, no offices, outsources all manufacturing and never has had plans to commercialize, so 🤷‍♂️. GLA✌️🍀🫈

0 · Reply

Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

Mar 16, 2026, 4:01 PM EDT - 19 days ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 2, 2026, 4:01 PM EST - 4 weeks ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Dec 3, 2025, 1:31 PM EST - 4 months ago

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

Dec 3, 2025, 7:01 AM EST - 4 months ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 4 months ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Nov 20, 2025, 8:57 AM EST - 4 months ago

Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout

Nov 6, 2025, 7:30 AM EST - 5 months ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 10, 2025, 4:32 AM EDT - 6 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC CHRS

Aug 25, 2025, 11:13 AM EDT - 7 months ago

Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash

Aug 7, 2025, 7:30 AM EDT - 8 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 10, 2025, 6:38 AM EDT - 10 months ago

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

May 29, 2025, 8:00 AM EDT - 11 months ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 12, 2025, 4:05 PM EDT - 11 months ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 25, 2025, 12:58 AM EDT - 1 year ago

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 13, 2025, 3:47 PM EDT - 1 year ago

Black Diamond Therapeutics: In Decline, But Why?

Mar 6, 2025, 4:01 PM EST - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dec 30, 2024, 3:07 PM EST - 1 year ago

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 3:24 PM EDT - 1 year ago

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 27, 2024, 10:38 AM EDT - 1 year ago

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 1, 2024, 10:00 AM EDT - 2 years ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2024, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 7, 2024, 6:00 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Mar 24, 2024, 11:25 PM EDT - 2 years ago

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

AAPL AER AMZN BA DFH DHI GE

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 2 years ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 12, 2024, 5:21 PM EST - 2 years ago

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 12, 2023, 8:31 AM EDT - 2 years ago

Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:53 AM EDT - 2 years ago

Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer Update

Jun 29, 2023, 8:57 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 6:51 PM EDT - 3 years ago

Black Diamond: On Right Track For Possible Accelerated Approval Pathway

Jun 28, 2023, 4:23 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Invest2live Apr. 4 at 2:24 PM

$NOK 105% already; congrats 🌿🎈🌿 Checkout $RXRX and $BDTX

0 · Reply

jarias115 Apr. 4 at 11:54 AM

$BDTX I love how this just jumps on no news.

1 · Reply

Knot2 Apr. 2 at 6:23 PM

$BDTX I’m in

0 · Reply

Stock_Squatch_Watcher Apr. 2 at 2:35 PM

$BDTX 😎✌️🫈

0 · Reply

captainblacktop Apr. 2 at 2:29 PM

$BDTX only thing I have that's green..

0 · Reply

Jafo333isme Apr. 1 at 7:59 PM

$BDTX today looks a lot like it traded on 2/24. Hmm...

0 · Reply

pzthk6 Apr. 1 at 2:03 PM

$BDTX Ive been in play for a long time, nice to see positive momentum. On good PR , this is a 200%+ jumper.

0 · Reply

frankwa Apr. 1 at 2:01 PM

$BDTX any news today to create the big pop in price?

0 · Reply

Stock_Squatch_Watcher Apr. 1 at 1:13 AM

$BDTX I get we are waiting on news, but dang this board is quiet 🤐 GLTA✌🍀🫈

0 · Reply

Stock_Squatch_Watcher Mar. 27 at 1:30 PM

0 · Reply

Stock_Squatch_Watcher Mar. 26 at 12:49 PM

$BDTX The Seeking Alpha article was a nice piece, but nothing not already known, so doubtful it has any real impact on pps. But, the current pps is quite humorous given the recent P2 results, let alone current cash on hand (which all but justifies a higher pps by itself). Expecting to see that the first brain study patient was dosed sometime in April, then the lung partner announced (hopefully) by end of 2Q. That should push this past $5.00, which is about where it was pre P2 data drop. ✌️🫈 Bullish

1 · Reply

Marklacey123 Mar. 25 at 1:55 PM

$BDTX NEW SEEKING ALPHA ARTICLE OUT.......Summary Black Diamond Therapeutics remains a 'Buy,' as silevertinib shows promising efficacy in EGFR-mutant NSCLC with notable CNS activity. BDTX reported a 60% objective response rate and 86% CNS response rate in phase 2 silevertinib data, addressing key resistance mutations. Cash position supports operations into 2028, allowing BDTX to reach pivotal clinical catalysts before requiring additional funding. Risks include competitive combination regimens and the need for future data to confirm silevertinib’s clinical and regulatory viability.

0 · Reply

Invest2live Mar. 18 at 8:22 PM

$ASRT 36% already; congrats. This has long way to go. Alerted several times. Congratulations 🎈 🎉🎊 Checkout $AKBA and $BDTX

0 · Reply

isaacsebring Mar. 17 at 5:09 PM

$BDTX Love how any catalyst can make this one pop. Can’t wait for big news!

0 · Reply

Marklacey123 Mar. 17 at 4:26 PM

$BDTX JEFFERIES REIT BUY PT $10, RAYMOND JAMES REIT BUY PT $11, STEIFEL REIT BUY PT $8

0 · Reply

erevnon Mar. 17 at 2:37 PM

Wedbush maintains Black Diamond Therapeutic $BDTX at Outperform and raises the price target from $13 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Marklacey123 Mar. 17 at 1:45 PM

$BDTX Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

0 · Reply

Stock_Squatch_Watcher Mar. 16 at 10:40 PM

$BDTX So earnings were in fact, today. 🙄🤷‍♂️ Great cash position, although once they begin the brain 🧠 trial it will require some $$, but should not have any dilution concerns for a year at least. The next 3 months are key with top line data coming and a partnership expected, otherwise why say new lung trial will begin in 2Q. I’m holding tight, not much risk if you are in at this pps range ($1.95-$2.25). ✌️🍀🦶🏿

2 · Reply

isaacsebring Mar. 16 at 2:16 AM

$BDTX hold this one gentleman! Been looking at forums in regards to the trial, and a lot of positive results! It’s a win for patients and investors. I like companies like this…

1 · Reply

Ramanda87 Mar. 12 at 3:54 PM

$BDTX I’m nearing the point where I’m going to reallocate my monies else where. You guys think this is moving soon?

2 · Reply

Stock_Squatch_Watcher Mar. 10 at 4:26 PM

$BDTX Hoping for (expecting) some solid update on the brain study and tangible news regarding lung study partner not just ”we are in discussions jargon” during earnings call. 🤞🍀🦶🏿

1 · Reply

fatpie68 Mar. 10 at 1:26 PM

I thought $BDTX was to release its ER before market today? What's up?

2 · Reply

Market Cap	136.92M
Revenue (ttm)	70.00M
Net Income (ttm)	22.37M
EPS (ttm)	N/A
PE Ratio	4.66
Forward PE	N/A
Profit Margin	31.96%
Debt to Equity Ratio	0.00

Volume	535,600
Avg Vol	646,216
Day's Range	N/A - N/A
Shares Out	57.29M
Stochastic %K	80%
Beta	3.38
Analysts	Strong Sell
Price Target	$9.71